Hepatology and Acute-on-Chronic Liver Failure
Yaqrit Limited focuses on clinical research in acute-on-chronic liver failure, with attention to advanced liver dysfunction in people with chronic liver disease and cirrhosis-related complications.
- ACLF
- Grade 1 to Grade 3 liver failure
- Extrahepatic organ failure
The company’s research activity is centered on severe liver disease states associated with high short-term mortality and multi-organ involvement.
Severe Alcoholic Hepatitis
Another key therapeutic area is severe alcoholic hepatitis, a serious inflammatory liver condition often overlapping with advanced hepatic decompensation.
- Alcohol-related liver injury
- Inflammatory liver disease
- Hepatic decompensation
Research in this area reflects a focus on patients with complex liver disease who require targeted clinical intervention.
Immunomodulatory and Inflammation-Related Therapies
The sponsor’s trial portfolio includes interest in therapies aimed at modulating immune activation and systemic inflammation in advanced liver disease.
- Granulocyte Colony-Stimulating Factor
- Innate immune response
- Inflammatory signalling
This therapeutic area is relevant to liver failure syndromes where immune dysregulation contributes to clinical deterioration.
Critical Care and Multi-Organ Dysfunction
Yaqrit Limited also engages in research involving critical care settings for patients with multi-organ dysfunction linked to advanced liver disease.
- Renal failure
- Coagulation abnormalities
- Respiratory and cardiovascular failure
These areas highlight clinical interest in managing the broader organ-system complications that accompany severe hepatic illness.
